Media formats available:
Recommended
- AHA 2019A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
Prof. Freek Verheugt, MD
Prof. Donald Lloyd-Jones
Prof. Scott Solomon
Prof. Freek Verheugt, MD
Prof. Donald Lloyd-Jones
Prof. Scott Solomon